Phase 2 Study: Tepotinib plus Gefitinib in MET plus /Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
JOURNAL OF THORACIC ONCOLOGY（2018）
关键词
EGFRI TKI-resistant non-small cell lung cancer,Gefitinib,Tepotinib,Anti-tumor activity
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要